Percutane hartklep implantatie bij congenitale en ... - KCE

More documents

Recommendations

Info

2 Percutaneous Heart Valves KCE Reports 95 7.2.2 Feasibility..........................................................................................................................................65 7.2.3 Safety.................................................................................................................................................65 7.2.4 Clinical effectiveness......................................................................................................................65 7.2.5 Cost effectiveness ..........................................................................................................................65 7.2.6 Scientific evaluation........................................................................................................................65 8 APPENDIX ..................................................................................................................... 67 9 REFERENCES................................................................................................................. 74
KCE Reports 95 Percutaneous Heart Valves 3 GLOSSARY ACC American College of Cardiology ACS Acute Coronary Syndrome AHA American Heart Association AMI Acute Myocardial Infarction AS Aortic Stenosis AVR Aortic Valve Replacement BACTS Belgian Association for Cardio-Thoracic Surgery BAV Balloon Aortic Valvuloplasty CABG Coronary Artery Bypass Grafting CA Competent Authority CAD Coronary Artery Disease CCOHTA Canadian Coordinating Office for Health Technology Assessment CHD Coronary Heart Disease CRD Centre for Reviews and Dissemination CVD Cardiovascular Disease ECC extracorporeal circulation EF Ejection Fraction EHS Euro Heart Survey ESC European Society of Cardiology EuroSCORE European System for Cardiac Operative Risk Evaluation FDA Food and Drug Administration HAS Haute Autorité de Santé HTA Health Technology Assessment HDE Humanitarian Device Exemption HUD Humanitarian Use Device ICER Incremental Cost-Effectiveness Ratio IDE Investigational Device Exemption IHD Ischemic Heart Disease INAHTA International Network of Agencies for Health Technology Assessment I-REVIVE Initial Registry of EndoVascular Implantation of Valves in Europe LVEF Left Ventricular Ejection Fraction MI Myocardial Infarction NB Notified Body NHS National Health Service NHSEED National Health Service Economic Evaluation Database NICE National Institute for Health and Clinical excellence NIHDI National Institute for Health and Disability Insurance (=RIZIV/INAMI) NYHA New York Heart Association PA/IVS Pulmonary Atresia with Intact Ventricular Septum PARTNER Placement of Aortic Transcatheter Valves Trial PAV Percutaneous Aortic Valve PHV Percutaneous Heart Valve PMA Pre-market Approval PPV Percutaneous Pulmonary Valve PS Pulmonary Stenosis PVT Percutaneous Valve Technologies QALY Quality Adjusted Life Year RCT Randomised Controlled Trial RECAST Registry of Endovascular Critical Aortic Stenosis Treatment RIZIV/INAMI National Institute for Health and Disability Insurance (Rijksinstituut voor Ziekte- en Invaliditeitsverzekering/National d’Assurance Maladie-Invalidité) (=NIHDI)
Page 1 and 2: Percutane hartklepimplantatie bij c
Page 3 and 4: Percutane hartklepimplantatie bij c
Page 5 and 6: KCE reports 95A Percutane hartklepi
Page 13: KCE Reports 95 Percutaneous Heart V
Page 17 and 18: KCE Reports 95 Percutaneous Heart V
Page 65 and 66:
KCE Reports 95 Percutaneous Heart V
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
KCE Reports vol Percutaneous Heart
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91:
Page 94 and 95:
Wettelijk depot : D/2008/10.273/79
Page 96 and 97:
38. Baarmoederhalskankerscreening e
show all

Percutane hartklep implantatie bij congenitale en ... - KCE

Create successful ePaper yourself

Delete template?

Save as template?